To Evaluate the Efficacy of Intravenous Infusion of Dexmedetomidine as Premedication in Attenuating the Rise of Intraocular Pressure Caused by Succinylcholine in Patients Undergoing Rapid Sequence Induction for General Anesthesia: A Randomized Study

Effect of dexmedetomidine on hemodynamic responses to tracheal intubation: A meta-analysis with meta-regression and trial sequential analysis

STUDY OBJECTIVE

An uncontrolled adrenergic response during tracheal intubation may lead to life-threatening complications. Dexmedetomidine binds to α2-receptors and may attenuate this response. The primary aim of our meta-analysis is to investigate dexmedetomidine efficacy in attenuating sympathetic response to tracheal intubation, compared with placebo or no dexmedetomidine, in terms of heart rate and blood pressure at intubation.

DESIGN

Meta-analysis with meta-regression and trial sequential analysis.

SETTING

Systematic search from inception until December 1, 2020 in the following databases: Pubmed, Scopus, the Cochrane Central Register of Controlled Trials, EMBASE and Google Scholar.

INTERVENTIONS

All randomized controlled trials investigating intravenous dexmedetomidine as premedication in adult patients undergoing tracheal intubation were included in our study. Studies were included without any language or publication date restriction. A trial sequential analysis and a post-hoc meta-regression were performed on the main outcomes.

MEASUREMENTS

Hemodynamic parameters and heart rate at tracheal intubation, dose of anesthetic needed for induction of anesthesia, total anesthetic requirement throughout the operative procedure, postoperative pain and percentage of patients requiring analgesics at 24 postoperative hours, postoperative nausea and vomiting, intraoperative and postoperative bradycardia, hypotension, dizziness, shivering and/or respiratory depression.

MAIN RESULTS

Ninety-nine included studies randomized 6833 patients. During laryngoscopy, all hemodynamic parameters were significantly greater in the no dexmedetomidine group. In particular, in the dexmedetomidine group, systolic blood pressure differed by -21.8 mm Hg (95% CI -26.6 to -17.1, p-value < 0.001, I² 97%), mean arterial pressure by -12.8 mm Hg (95% CI -15.6 to -10.0, p-value < 0.001, I² 98%), and heart rate by -16.9 bpm (95% CI -19.8 to -13.9, p-value < 0.001, I² 98%).

CONCLUSIONS

Patients receiving premedication with dexmedetomidine for tracheal intubation, compared with no dexmedetomidine, have a lower blood pressure and heart rate, however, the risk of bradycardia and hypotension is relevant and its use during daily practice should be cautiously evaluated for each patient.

Attenuation of the increase in intraocular pressure with dexmedetomidine: Systematic review with meta-analysis and trial sequential analysis

STUDY OBJECTIVE

Whether dexmedetomidine effectively attenuates the increase in intraocular pressure (IOP) remains inconclusive. We aim to evaluate the effects of dexmedetomidine on IOP in adult patients undergoing surgery which requires general anesthesia and endotracheal intubation.

DESIGN

Systematic review and meta-analysis.

INTERVENTIONS

Intravenous administration of dexmedetomidine during surgery.

MEASUREMENTS

Intraocular pressure.

METHODS

We searched PubMed, Embase, Scopus, Web of Science, Cochrane Library, Google Scholar, Wanfang Data, and China National Knowledge Infrastructure from the inception through April 14, 2020. Randomized control trials which involved adult patients undergoing surgery that required general anesthesia and endotracheal intubation, which compared intravenous administration of dexmedetomidine with placebo regarding the IOP levels, which also provided sufficient information for meta-analysis were considered eligible.

MAIN RESULTS

Twenty-nine randomized control trials were included. The IOP levels are significantly lower in patients receiving dexmedetomidine after the administration of dexmedetomidine [mean difference (MD), -2.04 mmHg; 95% confidence interval (CI), -2.40 mmHg to -1.67 mmHg], after the injection of succinylcholine (MD, -3.84 mmHg; 95% CI, -4.80 mmHg to -2.88 mmHg), after endotracheal intubation (MD, -3.64 mmHg; 95% CI, -4.46 mmHg to -2.82 mmHg), after pneumoperitoneum (MD, -3.12 mmHg; 95% CI, -3.93 mmHg to -2.30 mmHg), and after the patients being placed in a steep Trendelenburg position (MD, -4.12 mmHg; 95% CI, -5.39 mmHg to -2.85 mmHg). Trial sequential analyses for these outcomes are conclusive.

CONCLUSIONS

Dexmedetomidine effectively attenuates the increase in IOP levels, and should be considered especially for at-risk patients.